Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of RNK08954 in Patients With Advanced Solid Tumors With a KRAS G12D Mutation TRIAD1 (Trial of RNK08954 In KRAS G12D Mutation)

NCT06667544 is registered in ClinicalTrials.gov with Ranok Therapeutics (Hangzhou) Co., Ltd. as lead sponsor.

NCT NCT06667544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06667544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of RNK08954 in Patients With Advanced Solid Tumors With a KRAS G12D Mutation TRIAD1 (Trial of RNK08954 In KRAS G12D Mutation)
Lead sponsor
Ranok Therapeutics (Hangzhou) Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 8, 2024
Completion date
July 31, 2027
Enrollment
152 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

kras g12d mutation